SpaceX's First Earnings Post IPO
Amylyx Pharmaceuticals Inc AMLX
$20.31
▼ -2.12%
($-0.44)
📅 Earnings This Week
Open
$20.74
Prev Close
$20.75
Day Range
$19.30 – $20.87
52W Range
$7.48 – $20.21
Market Cap
$2.26B
Beta
-0.21
EPS (TTM)
$-1.51
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2022-01-07 |
| Shares Out. | 111,190,000 |
| Website | amylyx.com/ ↗ |
| Phone | 13026365400 |
| Employees | 136 |
| Net Income | -$41.3M |
| Free Cash Flow | -$120.5M |
| Total Assets | $293.6M |
| Total Liabilities | $20.4M |
| Equity | $273.2M |
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
Amylyx Pharmaceuticals Inc is a publicly traded company under the ticker symbol AMLX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-07-01)